Cambium Bio Limitedformerly Known As Regeneus Ltdis An Australia Based Clinical Stage Regenerative Medicine Company Listed On The Australian Securities Exchange Under The Code Cmbthe Company Specializes In Developing Biologics For Ophthalmology And Tissue Repairutilizing Stem Cell Technology And Human Platelet Lysate Cambium Bio S Lead Product Candidateelate Ocularis Designed To Treat Dry Eye Disease And Is Derived From Human Platelet Lysate Sourced From Younger Donorsthe Company Also Offers Progenzaa Stem Cell Platform For Knee Osteoarthritis And Tissue Repairand Sygenuswhich Focuses On Wound Healingadditionallycambium Bio Produces Stem Cell Growth Supplementsincluding Ultragro Advancedultragro Pureand Ultragro Pure Giwith The Latter Two Being Xeno Free The Company Is Led By Ceo Mrkarolis Rosickas And Is Headquartered In Paddingtonaustraliain 2024Cambium Bio Completed A Merger With Cambium Medical Technologiesllcenhancing Its Capabilities In Regenerative Medicine
